Fidelity Investments
BDTX icon

Fidelity Investments’s Black Diamond Therapeutics BDTX Stock Holding History

Fidelity Investments’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.33M Buy
623,827
+82,673
+15% +$197K ﹤0.01% 2775
2025
Q4 		$1.32M Buy
541,154
+87,596
+19% +$310K ﹤0.01% 2748
2025
Q3 		$1.72M Buy
453,558
+39,672
+10% +$116K ﹤0.01% 2599
2025
Q2 		$1.03M Buy
413,886
+75,217
+22% +$145K ﹤0.01% 2712
2025
Q1 		$525K Buy
338,669
+142,542
+73% +$299K ﹤0.01% 2882
2024
Q4 		$420K Buy
196,127
+17,059
+10% +$48.9K ﹤0.01% 2996
2024
Q3 		$779K Buy
+179,068
New +$974K ﹤0.01% 2683
2024
Q1 		– Sell
-2
Closed -$6 – 5369
2023
Q4 		$6 Hold
2
– – ﹤0.01% 5359
2023
Q3 		$6 Sell
2
-16
-89% -$59 ﹤0.01% 5211
2023
Q2 		$92 Sell
18
-66
-79% -$135 ﹤0.01% 4969
2023
Q1 		$158 Buy
84
+75
+833% +$172 ﹤0.01% 4869
2022
Q4 		$16 Sell
9
-281
-97% -$506 ﹤0.01% 5164
2022
Q3 		$0 Buy
290
+254
+706% +$783 ﹤0.01% 4854
2022
Q2 		$0 Sell
36
-14,622
-100% -$34K ﹤0.01% 4916
2022
Q1 		$41K Buy
14,658
+14,649
+162,767% +$53.5K ﹤0.01% 3741
2021
Q4 		$0 Hold
9
– – ﹤0.01% 4333
2021
Q3 		$0 Sell
9
-360,420
-100% -$3.56M ﹤0.01% 4339
2021
Q2 		$4.39M Sell
360,429
-1,730,859
-83% -$34.2M ﹤0.01% 2364
2021
Q1 		$50.7M Buy
2,091,288
+429,631
+26% +$11.6M ﹤0.01% 1396
2020
Q4 		$53.3M Buy
1,661,657
+264,005
+19% +$8.67M ﹤0.01% 1291
2020
Q3 		$42.3M Sell
1,397,652
-27,283
-2% -$830K ﹤0.01% 1261
2020
Q2 		$60.1M Sell
1,424,935
-163,075
-10% -$6M 0.01% 1088
2020
Q1 		$39.6M Buy
+1,588,010
New +$48.3M 0.01% 1120

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Fidelity Investments's BDTX Position: Q1 2026 in Review

Fidelity Investments increased its Black Diamond Therapeutics (BDTX) stake by 15% in Q1 2026, buying an estimated $197K and bringing the position to 623,827 shares worth $1.33M. The position accounts for ﹤0.01% of the portfolio, ranked #2775.

Fidelity Investments first reported a position in BDTX in Q1 2020 and has held it in 23 quarters since. The position peaked at $60.1M in Q2 2020. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

  • Fidelity Investments held 623,827 shares of Black Diamond Therapeutics worth $1.33M as of Q1 2026.
  • Fidelity Investments bought 82,673 Black Diamond Therapeutics shares in Q1 2026, an estimated $197K.
  • Black Diamond Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #2775 holding.
  • Fidelity Investments first reported a position in Black Diamond Therapeutics in Q1 2020 and has held it in 23 quarters since.
  • Fidelity Investments's Black Diamond Therapeutics position peaked at $60.1M in Q2 2020.
  • 104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.